a phase ii trial of ruxolitinib and azacitidine combination therapy in patients with myelofibrosis
Published 1 month ago • 115 plays • Length 2:39Download video MP4
Download video MP3
Similar videos
-
8:03
phase ii trial of navitoclax and ruxolitinib in high-risk r/r myelofibrosis
-
2:15
a phase i study investigating ruxolitinib and abemaciclib for primary or secondary myelofibrosis
-
7:42
phase ii trial of bomedemstat for advanced myelofibrosis
-
2:11
update on phase i/ii study of azacitidine, venetoclax and gilteritinib in patients with flt3 aml
-
1:34
pelabresib in myelofibrosis: the manifest trials
-
1:49
phase ii trial-in-progress of itacitinib in patients with myelofibrosis
-
1:25
phase ii trial of eprenetapopt plus azacitidine: long-term follow up
-
1:35
phase i study of plx51107, a novel bet inhibitor, in combination with azacitidine in r/r mds and aml
-
1:20
the impact of early ruxolitinib treatment on os in the comfort-i and comfort-ii studies
-
1:02
a phase ii single-arm study of obinutuzumab plus ibrutinib as frontline treatment for fl and mzl
-
2:04
introducing a phase ib/ii trial to evaluate tasquinimod for the treatment of myelofibrosis
-
1:15
ongoing trials of ruxolitinib, momelotinib and imetelstat in myelofibrosis
-
1:38
phase ii trial of luspatercept in myelofibrosis-associated anemia
-
2:04
phase i/ii study of a novel bet inhibitor, bms-986158, alone & with ruxolitinib or fedratinib in mf
-
1:52
an update on the use of navtemadlin in myelofibrosis
-
1:58
novel myelofibrosis-associated anemia treatments in phase ii trials
-
2:25
results from a phase i/ii trial of pirtobrutinib and lv20.19 for patients with r/r lymphomas
-
2:58
long-term follow-up: phase ii study of apr-246 aza in tp53-mutated mds & aml